Handelsavisen
prelaunch
Companies Healthcare 6891.TWO
68
6891.TWO TPEx Biotechnology & Medical Research

6891.Two

$50,60
Open in Charts → Attach watcher ⌖
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
10,1B TWD
P/E
EV / Rev
Div yield
0,00 %
Op margin
-1 370,5 %
ROE
-11,7 %
Net margin
-1 425,2 %
Debt / equity
0,19
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

6891.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.

Business. 6891.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-11,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 6891.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 6891.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    6891.TWO is a biotechnology and medical research company operating in the healthcare sector, primarily generating revenue through pharmaceuticals and medical research activities.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a high proportion of equity, with total equity of TWD 155.08 billion and total liabilities of TWD 34.53 billion, resulting in a debt-to-equity ratio of 0.19. The company maintains a strong liquidity position, with cash and equivalents amounting to TWD 69.86 billion, and a current ratio of 13.58, indicating a robust ability to meet short-term obligations. However, the company is currently unprofitable, with a net loss of TWD 18.15 billion and an operating loss of TWD 17.46 billion, resulting in a negative return on equity of -11.71% and a negative return on assets of -9.57%.

    The company's financial performance is significantly below the industry median for profitability metrics. The negative return on equity and return on assets suggest poor capital efficiency and operational performance. The company's price-to-book ratio of 7.25 and price-to-tangible-book ratio of 7.25 indicate that the market is valuing the company's equity at a premium relative to its book value, despite the current unprofitability. The enterprise value to revenue ratio of 851.09 is extremely high, suggesting that the market is placing a very high valuation on the company's revenue, which may not be justified by its current earnings performance.

    The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no specific geographic breakdown provided. This lack of diversification may expose the company to higher risk if the segment or region experiences a downturn. The absence of detailed segment or geographic data limits the ability to assess the company's exposure to different markets.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The company reported a significant net loss and negative operating income, which may indicate challenges in scaling operations or achieving profitability. The capital expenditure of TWD 432.04 billion suggests a high level of investment in infrastructure or expansion, but the negative free cash flow of TWD 581.40 billion indicates that the company is not generating sufficient cash to fund these investments internally.

    The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating and net income, combined with high capital expenditures, may increase the risk of future dilution if the company needs to raise additional capital to fund operations or growth initiatives. The absence of dilution sources in the risk assessment suggests that the company has not disclosed any immediate plans for equity issuance or other dilutive actions.

    Recent events, as reflected in the financial snapshot, include a significant net loss and negative operating income, which may be indicative of operational challenges or market pressures. The company's high capital expenditures and negative free cash flow suggest that it is investing heavily in growth, but the lack of profitability may raise concerns about the sustainability of these investments. The absence of specific recent filings or transcripts limits the ability to assess the company's strategic direction or management commentary.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 13.58 and TWD 69.86 billion in cash and equivalents.
    • The company is currently unprofitable, with a net loss of TWD 18.15 billion and an operating loss of TWD 17.46 billion.
    • The company's valuation metrics, such as the price-to-book ratio of 7.25 and enterprise value to revenue ratio of 851.09, suggest a high market valuation despite current unprofitability.
    • The company's capital expenditures are significant, but the negative free cash flow indicates that it is not generating sufficient internal cash to fund these investments.
    • The company's risk profile is characterized by low liquidity and dilution risk, but the lack of profitability and high capital expenditures may increase the risk of future dilution.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $50,60
    Market cap
    $11.24B
    Enterprise value
    $10.84B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    7.2x
    P / Tangible book
    7.2x
    Tangible book
    $1.55B
    Net cash
    $400.0M
    Current ratio
    13.6
    Debt / equity
    0.2
    ROA
    -9.6%
    ROE
    -11.7%
    Cash conversion
    93.0%
    CapEx / revenue
    -33.9%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-1 370,5 %Bottom quartile
    Net Margin-1 425,2 %Bottom quartile
    ROE-11,7 %Above median
    Capex / Rev-3 391,7 %Bottom quartile
    D/E0,19Below median
    Cash Conv0,93Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 6891.TWO Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    6891.TWOCanonical
    TPEx · TWD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage